终末期肝病血管活性物抵抗发生机制与诊疗关系的争议和对策

刘建军; 郑文凯; 王江红; 任燕军; 刘研; 赵利珍

doi:10.3969/j.issn.1001-5256.2022.10.040

终末期肝病血管活性物抵抗发生机制与诊疗关系的争议和对策

DOI: 10.3969/j.issn.1001-5256.2022.10.040

河北省邯郸市第二医院消化内科，河北邯郸 056001

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：刘建军负责选题，收集分析资料，撰写文章及定稿；郑文凯、王江红、任燕军、刘研负责选题，收集分析资料，撰写文章；赵利珍负责选题，整理资料，修改文章及定稿。

详细信息

通信作者:
赵利珍，834736335@qq.com

计量
- 文章访问数: 332
- HTML全文浏览量: 74
- PDF下载量: 33
- 被引次数: 0
出版历程
- 收稿日期: 2022-06-14
- 录用日期: 2022-07-25
- 出版日期: 2022-10-20

Vasoactive substance resistance mechanisms in diagnosis and treatment of end-stage liver diseases: Disputes and counter-measurement

Department of Gastroenterology, The Second Hospital of Handan City, Handan, Hebei 056001, China

More Information

Corresponding author: ZHAO Lizhen, 834736335@qq.com(ORCID: 0000-0001-9748-2509)

摘要

摘要: 终末期肝病(ESLD)血管活性物(VS)抵抗是指患者对内、外源性VS反应性和心脏、血管兴奋性降低，周围循环功能障碍及诱发相关不良事件的现象。VS抵抗与ESLD相关并发症的发病机制、诊断和治疗密切相关，但仍存在较多争议问题，包括：(1)ESLD患者发生VS抵抗的原因和机制；(2)VS抵抗与ESLD多器官损伤的关系；(3)如何预防与缓解VS抵抗；(4)ESLD患者发生VS抵抗的血管活性药物使用问题等。本文就上述问题提出商榷，旨在探讨如何防止与缓解ESLD患者VS抵抗以及减少相关不良事件发生。
- 终末期肝病 /
- 血管收缩药 /
- 血管舒张药
Abstract: The vasoactive substance resistance (VSR) in the end-stage liver disease (ESLD) refers as the reduction of patients' responsiveness to endogenous and exogenous vasoactive substances, cardiac and vascular excitability, peripheral circulatory dysfunction, but induction of related adverse events. VSR is closely related to pathogenesis and treatment-related ESLD complications. However, to date, there are so many unsolved issues, like 1). The cause and underlying mechanism of VSR in ESLD patients; 2). VSR and ESLD multiple organ damages; 3). The preventive and mitigated measurement of VSR; and 4). VSR vasoactive drug use in ESLD patients. This review discussed and summarized the up to date progress in this field of research and clinical VSR in patients with ESLD, i.e., VRS in ESLD patients, disputes of vasoconstrictor drug therapy in ESLD patients, and future research direction of the field.
- End-Stage Liver Disease /
- Vasoconstrictor Agents /
- Vasodilator Agents

HTML全文

参考文献(27)

[1]	LI XY, HUA J. Treatment of hepatorenal syndrome: Vasoconstriction or vasodilation?[J]. J Clin Hepatol, 2020, 36(11): 2419-2422. DOI: 10.3969/j.issn.1001-5256.2020.11.005. 李晓芸, 华静. 肝肾综合征的治疗: 缩血管还是扩血管治疗?[J]. 临床肝胆病杂志, 2020, 36(11): 2419-2422. DOI: 10.3969/j.issn.1001-5256.2020.11.005.
[2]	XU XY, ZHENG YY. Hepatorenal syndrome-vasoconstrictor or vasodilator?[J]. J Clin Hepatol, 2011, 27(8): 801-803, 817. http://lcgdbzz.org/article/id/LCGD201108005 徐小元, 郑颖颖. 肝肾综合征——缩血管还是扩血管?[J]. 临床肝胆病杂志, 2011, 27(8): 801-803, 817. http://lcgdbzz.org/article/id/LCGD201108005
[3]	AMIN AA, ALABSAWY EI, JALAN R, et al. Epidemiology, pathophysiology, and management of hepatorenal syndrome[J]. Semin Nephrol, 2019, 39(1): 17-30. DOI: 10.1016/j.semnephrol.2018.10.002.
[4]	BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048. DOI: 10.1002/hep.31884.
[5]	LIU JJ, ZHENG WK, WANG JH, et al. Questioning and clinical practice of the 2021 American Society of Hepatology guidelines for the diagnosis, evaluation and management of ascites and hepatorenal syndrome[J]. Chin J Gastroenterol Hepatol, 2022, 31(2): 121-125. DOI: 10.3969/j.issn.1006-5709.2022.02.001. 刘建军, 郑文凯, 王江红, 等. 对2021年美国肝病学会腹水和肝肾综合征的诊断、评估和管理指南的质疑与临床实践[J]. 胃肠病学和肝病学杂志, 2022, 31(2): 121-125. DOI: 10.3969/j.issn.1006-5709.2022.02.001.
[6]	PIANO S, SCHMIDT HH, ARIZA X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(11): 1792-1800. e3. DOI: 10.1016/j.cgh.2018.01.035.
[7]	VELEZ J, THERAPONDOS G, JUNCOS LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis[J]. Nat Rev Nephrol, 2020, 16(3): 137-155. DOI: 10.1038/s41581-019-0218-4.
[8]	GINÈS P, SOLÀ E, ANGELI P, et al. Hepatorenal syndrome[J]. Nat Rev Dis Primers, 2018, 4(1): 23. DOI: 10.1038/s41572-018-0022-7.
[9]	Chinese Society of Hepatology and Chinese Society of lnfectious Diseases. Guidelines for diagnosis and treatment of cirrhotic ascites and related complications[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001.5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001.5256.2017.10.003.
[10]	SCHRIER RW, ARROYO V, BERNARDI M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis[J]. Hepatology, 1988, 8(5): 1151-1157. DOI: 10.1002/hep.1840080532.
[11]	ADEBAYO D, NEONG SF, WONG F. Refractory ascites in liver cirrhosis[J]. Am J Gastroenterol, 2019, 114(1): 40-47. DOI: 10.1038/s41395-018-0185-6.
[12]	KAZORY A, RONCO C. Hepatorenal syndrome or hepatocardiorenal syndrome: revisiting basic concepts in view of emerging data[J]. Cardiorenal Med, 2019, 9(1): 1-7. DOI: 10.1159/000492791.
[13]	FENG LJ, JIA JD. Consensus and controversy on diagnosis and treatment of complications of liver cirrhosis[J]. Chin Hepatol, 2022, 27(1): 4-8. DOI: 10.3969/j.issn.1008-1704.2022.01.002. 冯丽娟, 贾继东. 关于肝硬化并发症诊治的共识与争议[J]. 肝脏, 2022, 27(1): 4-8. DOI: 10.3969/j.issn.1008-1704.2022.01.002.
[14]	WANG L, LONG Y, LI KX, et al. Pharmacological treatment of hepatorenal syndrome: a network meta-analysis[J]. Gastroenterol Rep (Oxf), 2020, 8(2): 111-118. DOI: 10.1093/gastro/goz043.
[15]	MINDIKOGLU AL, PAPPAS SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 162-177. e1. DOI: 10.1016/j.cgh.2017.05.041.
[16]	KIM HY, CHO EJ, CHUN S, et al. Red blood cell alloimmunization in Korean patients with myelodysplastic syndrome and liver cirrhosis[J]. Ann Lab Med, 2019, 39(2): 218-222. DOI: 10.3343/alm.2019.39.2.218.
[17]	ARORA V, MAIWALL R, RAJAN V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J]. Hepatology, 2020, 71(2): 600-610. DOI: 10.1002/hep.30208.
[18]	MOORE K, JAMIL K, VERLEGER K, et al. Real world treatment patterns and outcomes usingterlipressin in 203 patients with the hepatorenal syndrome[J]. Aliment Pharmacol Ther, 2020, 52(2): 351-358. DOI: 1111/apt.15836.
[19]	ANGELI P, GARCIA-TSAO G, NADIM MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document[J]. J Hepatol, 2019, 71(4): 811-822. DOI: 10.1016/j.jhep.2019.07.002.
[20]	SOLÀ E, SOLÉ C, SIMÓN-TALERO M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial[J]. J Hepatol, 2018, 69(6): 1250-1259. DOI: 10.1016/j.jhep.2018.08.006.
[21]	HIRAMINE Y, UTO H, MAWATARI S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites[J]. Hepatol Res, 2019, 49(7): 765-777. DOI: 10.1111/hepr.13337.
[22]	NGUYEN-TAT M, JÄGER J, REY JW, et al. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2[J]. United European Gastroenterol J, 2019, 7(4): 529-537. DOI: 10.1177/2050640619825719.
[23]	QIN YX, LONG FL, MAO DW, et al. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome: A Meta-analysis[J]. J Clin Hepatol, 2019, 35(10): 2266-2271. DOI: 10.3969/j.issn.1001-5256.2019.10.027. 覃艳新, 龙富立, 毛德文, 等. 去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性比较的Meta分析[J]. 临床肝胆病杂志, 2019, 35(10): 2266-2271. DOI: 10.3969/j.issn.1001-5256.2019.10.027.
[24]	LIU JJ, NIU B. Interpretation and Discussion on the 2017 guidelines for the diagnosis and treatment of cirrhosis ascites and related complications[J]. New Chin Med, 2018, 49(1): 1-5. DOI: 10.3969/j.issn.0253-9802.2018.01.001. 刘建军, 牛蓓. 对2017年《肝硬化腹水及相关并发症的诊疗指南》的解读与商榷[J]. 新医学, 2018, 49(1): 1-5. DOI: 10.3969/j.issn.0253-9802.2018.01.001.
[25]	WEI L, YI WY, LIU ZJ, et al. Clinical significance of B-type natriuretic peptide in patients with liver cirrhosis[J]. Chin J Clin Res, 2017, 20(8): 1076-1077. DOI: 10.13429/j.cnki.cjcr.2017.08.020. 韦玲, 易文轶, 刘正金, 等. 肝硬化患者B型利钠肽检测的临床意义[J]. 中国临床研究, 2017, 20(8): 1076-1077. DOI: 10.13429/j.cnki.cjcr.2017.08.020.
[26]	WONG F, MOORE K, DINGEMANSE J, et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome[J]. Hepatology, 2008, 47(1): 160-168. DOI: 10.1002/hep.21940.
[27]	LIU JJ, NIU B. Relationship between pathogenesis of end-stage liver disease and hyponatremia and its countermeasures[J]. Chin J Clin Gastroenterol, 2015, 27(3): 189-192. DOI: 10.3870/lcxh.j.issn.1005-541x.2015.03.21. 刘建军, 牛蓓. 终末期肝病发病机制与低钠血症的关系和对策[J]. 临床消化病杂志, 2015, 27(3): 189-192. DOI: 10.3870/lcxh.j.issn.1005-541x.2015.03.21.